Company profile: Vicore Pharma
1.1 - Company Overview
Company description
- Provider of pharmaceuticals for severe lung disorders, developing drugs acting through the angiotensin II type 2 (AT2) receptor, including buloxibutid (C21), an orally available ATRAG in phase 2a for idiopathic pulmonary fibrosis (IPF) with orphan drug designation in the EU, and Almee, a digital therapeutic based on cognitive behavioral therapy to address the psychological impact of pulmonary fibrosis.
Products and services
- Buloxibutid (C21): Orally available ATRAG activating the angiotensin II type 2 receptor, phase 2a for idiopathic pulmonary fibrosis, EU orphan-designated, engineered to improve IPF treatment
- AT2 receptor–targeted drug development: Vicore architects medicines acting through the angiotensin II type 2 receptor to address severe lung disorders, utilizing receptor-specific research to create AT2-focused therapeutics
- Almee™: A CBT-based digital therapeutic architected to address the psychological impact of living with pulmonary fibrosis, designed to support patients’ mental health needs associated with the disease.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vicore Pharma
Pfizer
HQ: United States
Website
- Description: Provider of biopharmaceutical medicines and health care services, delivering affordable access to safe, effective treatments, including vaccines for infectious diseases (COVID-19, pneumonia, meningitis), oncology therapies, cardiovascular medicines for hypertension and cholesterol, anti-infectives (antibiotics, antivirals), treatments for inflammation and immunology, and therapies for rare genetic disorders addressing unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pfizer company profile →
Senda Biosciences
HQ: United States
Website
- Description: Provider of a therapeutics platform leveraging insights into molecular connections between humans, offering Endless RNA (eRNA) to program proteins inside the body with long-lasting expression, Natural NanoParticle (NNP) technology with nanoparticles derived from nature for targeted delivery of biomolecules into human cells, and AI-driven integrative design of RNA medicines for oncology and rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Senda Biosciences company profile →
Vactech
HQ: Finland
Website
- Description: Provider of early-stage product candidates focused on Type 1 Diabetes, Celiac Disease, Asthma & Allergy, and diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vactech company profile →
TesoRx
HQ: United States
Website
- Description: Provider of virtual pharmaceutical development and commercialization, offering TSX-049, an oral testosterone undecanoate for male hypogonadism with once-daily dosing without a high-fat meal; a neoliposomal drug delivery platform enhancing bioavailability via GI lymphatic absorption; licensing and joint development agreements; and clinical trials evaluating TSX-049, with anticipation of FDA approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TesoRx company profile →
Rosemont Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of oral liquid medicines for patients with swallowing difficulties, manufacturing and supplying 130+ formulations across therapeutic categories. Offers R&D for new low-excipient liquid medications, GMP and ICH Q10-compliant, regularly inspected manufacturing, international distribution to 27+ markets, and educational resources for healthcare professionals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rosemont Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vicore Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vicore Pharma
2.2 - Growth funds investing in similar companies to Vicore Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vicore Pharma
4.2 - Public trading comparable groups for Vicore Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →